What Дуспаталин treats: main uses and benefits

Дуспаталин is a medication primarily used to manage symptoms associated with functional gastrointestinal disorders. Its active ingredient, mebeverine, belongs to a group of medicines known as antispasmodics, which act directly on the smooth muscles of the digestive tract.

Primary Indications

The medication is most commonly used for the symptomatic relief of conditions affecting the colon and the small intestine. Key applications include:

• Irritable Bowel Syndrome (IBS): It is frequently utilized to alleviate the characteristic symptoms of IBS, such as abdominal pain, cramping, persistent diarrhea, or alternating constipation.
• Gastrointestinal Spasms: The drug helps reduce muscle contractions in the gut that cause discomfort or pain.
• Functional Bowel Disorders: It is used to manage abdominal distress and bowel habit changes that do not have an underlying structural or biochemical cause.

How It Works and Benefits

The primary benefit of Дуспаталин lies in its targeted action. Unlike some other treatments for digestive issues, its mechanisms provide specific advantages for patients:

• Selective Muscle Relaxation: The medication works by relaxing the smooth muscles of the gut wall. This helps normalize intestinal motility without completely blocking normal bowel movements.
• Reduction of Pain: By easing the intensity and frequency of spasms, it helps reduce the sharp or dull aching sensations associated with digestive episodes.
• Minimal Systemic Impact: Because it focuses specifically on the gastrointestinal tract, it generally does not interfere with the autonomic nervous system, reducing the likelihood of certain side effects often seen with older antispasmodic drugs.

Who Can and Cannot Use Дуспаталин (Mebeverine)

Official regulatory guidelines define specific populations for whom Дуспаталин is authorized, restricted, or absolutely prohibited. This information is based strictly on governmental labeling, such as the Summary of Product Characteristics (SmPC).

Eligibility and Restrictions

Category	Regulatory Status
Adults and the Elderly	Use is established and generally permitted. No dosage adjustment is typically required for older adults.
Children and Adolescents (Under 18)	Not Recommended. Use is restricted due to insufficient data regarding safety and efficacy in this age group.
Pregnant Women	Not Recommended. Use is restricted because human data on safety during pregnancy is limited.
Breastfeeding Women	Should Not Be Used. It is unknown if the active substance is excreted in human milk.
Renal/Hepatic Impairment	Conditional Use. For non-advanced impairment, no dosage adjustment is usually necessary. Caution is advised for patients with advanced liver or kidney disease.

Absolute Contraindications

Дуспаталин is strictly contraindicated (must not be used) for patients with a known hypersensitivity or allergy to Mebeverine hydrochloride or any of the product's inactive ingredients (excipients). Absolute prohibition also applies to patients with certain rare hereditary problems, such as galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption, if those excipients are present in the specific formulation being used.

Interactions with other medicines and products

Official regulatory information for mebeverine hydrochloride (Дуспаталин) consistently states that the drug has a minimal documented interaction profile.

Interaction Scope and Regulatory Findings

Category	Official Regulatory Statement
Documented Drug-Drug Interactions	None documented. Official government regulatory sources state that no interactions with other medicinal products are known or formally recorded in the prescribing information.
Pharmacokinetic Interactions	None documented. Mebeverine is primarily metabolized by esterases (hydrolysis), not through the major Cytochrome P450 (CYP) enzyme system, minimizing the risk of CYP-mediated interactions.
Timing Requirements	None documented. No mandatory separation windows or timing constraints are specified for co-administration with other medicines based on interaction risk.

Interaction with Other Substances

The most specific finding in regulatory documentation concerns ethanol.

• Alcohol (Ethanol): No Interaction Demonstrated. Official studies have confirmed the absence of any interaction between mebeverine hydrochloride and ethanol (alcohol), as stated in regulatory summaries.
• Food and Herbal Products: No specific interactions with food, supplements, or herbal products are formally documented in official prescribing information.

This lack of known interactions, as confirmed by regulatory authorities, means the official interaction profile does not require restrictions or prohibitions regarding the co-administration of most other medicinal products.

Direct Musculotropic Mechanism

The active ingredient, mebeverine, primarily acts on the smooth muscle cells of the gastrointestinal (GI) tract. Its core mechanism involves modulating L-type voltage-dependent calcium channels (Cav1.2). By functioning as an inhibitor, mebeverine restricts the inward flux of calcium ions (Ca^2+) necessary for muscle depolarization and sustained contraction. This interference with the excitation-contraction coupling process directly initiates the relaxation of hyper-contractile smooth muscle fibers while preserving baseline intestinal peristaltic function.

Local Neuro-Modulation

Mebeverine also exerts a local anesthetic-like effect by modulating sodium channels on the afferent nerve endings within the enteric wall. This action restricts the depolarization threshold of these local sensory nerves, modulating the activation of visceral mechanoreceptors in response to physical distension. The overall mechanism is highly peripheral, confining its effects to the GI musculature and local nervous system.

The administration of Mebeverine hydrochloride is characterized by distinct patterns for its two common oral dosage forms: 135 mg tablets and 200 mg prolonged-release capsules. The medicine is intended solely for oral use.

Administration Dosing and Timing

Dosage Form	Standard Regimen	Timing and Method
135 mg Tablet	One tablet, three times daily (TID)	Preferably 20 minutes before a meal, swallowed whole with water.
200 mg Capsule	One capsule, twice daily (BID)	Preferably 20 minutes before a meal, swallowed whole with water.

To ensure proper release of the active ingredient, neither the tablet nor the prolonged-release capsule must be chewed, crushed, or broken. This constraint is critical for the 200 mg prolonged-release form, which relies on being swallowed intact to ensure the active ingredient is released slowly over time.

Dose Management and Special Rules

The duration of therapy with Mebeverine is generally not limited and may be continued until the desired effect is achieved. The dose may be gradually reduced after symptoms have been controlled for several weeks. If a dose is missed, the standard procedure is to skip the missed dose and take the next one at the usual time; doubling the dose to compensate is not recommended.

Furthermore, for the 135 mg and 200 mg strengths, the medicine is not recommended for use in children and adolescents under 18 years, though no dosage adjustments are deemed necessary for older adults or patients with renal or hepatic impairment.

Research evidence / Overview of studies for Дуспаталин

---

Evidence for Use in Irritable Bowel Syndrome (IBS) and Functional Disorders

The main body of research for mebeverine was studied in the context of symptoms of Irritable Bowel Syndrome (IBS), a condition characterized by fluctuating or episodic manifestations. These studies primarily utilized short-term randomized controlled trials (RCTs) in adult populations. Research examined outcomes related to physical discomfort, such as the intensity and frequency of abdominal cramping, and used patient-reported outcomes describing perceived discomfort.

When analyzing the findings, research describes patterns observed in the studies, particularly measurements related to changes in the intensity and frequency of these symptoms. While some trials reported how symptoms evolved in the observed populations, systematic reviews indicate that findings were mixed regarding overall patient-reported global improvement. The evidence contributes to the broader evidence landscape but has been primarily focused on short-term observation periods.

Research on Different Formulations: Tablets vs. Prolonged-Release Capsules

Studies have also explored the two available forms of mebeverine. Research examined how the body processes the two formulations to confirm pharmacokinetic parameters. Studies were conducted to compare whether both formulations resulted in comparable outcomes related to physical discomfort.

These studies monitored outcomes related to physical discomfort and reported results suggesting comparable patterns of symptom reporting to the standard tablet form. Research examined questions of clinical similarity, not necessarily superiority, between the two formulations.

What is Still Uncertain About the Research Evidence

The available evidence contributes to understanding symptom patterns, but several research limitation frames are present across the existing studies. The follow-up durations were limited in many of the core studies, meaning long-term effects are not fully established beyond the typical trial period of a few weeks or months.

Furthermore, data for certain groups remain insufficient, including pregnant or breastfeeding populations, or older adults with co-occurring health issues. The research provides context but not individual predictions, and the findings describe group patterns, not personal outcomes.

Common questions about Дуспаталин (FAQ)

---

Q: What should I do if I accidentally take too much of the medicine?

If a person takes too much of this medicine (an overdose), official regulatory documents recommend contacting a doctor or presenting to a hospital emergency department straight away. It is also recommended to take the medicine packaging with you to share the relevant details with healthcare professionals.

---

Q: What should I do if I get a bad reaction or allergy to a pill (like swelling of the face)?

If a person experiences any signs of a serious allergic reaction, such as difficulty breathing or swelling of the face, neck, tongue, or throat (known as angioedema), regulatory guidance suggests discontinuing the medicine immediately. Official product information emphasizes seeking immediate emergency medical attention for such severe reactions.

---

Q: What are the common side effects of Mebeverine, and what should I watch out for?

According to official regulatory information, all documented adverse effects for this medicine are classified as 'Frequency Not Known,' meaning the exact rate of incidence cannot be reliably estimated from available data. The adverse effects reported primarily relate to hypersensitivity reactions, which include skin issues like rash, urticaria (hives), and swelling of the face or throat.

---

Q: How long can I continue taking Mebeverine for my IBS symptoms?

Official prescribing information notes that the duration of therapy with mebeverine is generally not limited and may be continued until the desired effect of symptom control is achieved. The guidance also permits that the dose can be gradually reduced after symptoms have been controlled for several weeks.

---

Q: Is there any strong evidence or studies showing that Mebeverine works well for IBS?

The main body of research for mebeverine has focused on its use for symptoms of Irritable Bowel Syndrome (IBS). Studies were primarily short-term controlled trials. Official reports indicate that findings regarding overall patient-reported global improvement in symptoms have been mixed.

---

Q: What is the exact way Mebeverine works to stop the cramping in the bowel?

Mebeverine is formally classified as a musculotropic antispasmodic. Studies cited in official product information show that its primary action is direct relaxation of the smooth muscle fibers in the wall of the gastrointestinal tract, which helps to stop painful spasms and cramping.

---

Q: Can women who are pregnant or trying to conceive take this medication?

Regulatory documents state that use is not generally recommended for pregnant women because there is limited human data on safety during pregnancy. Official guidance recommends that people who are pregnant, or planning to be, consult a healthcare professional before use.

The official regulatory guidelines outline specific requirements for storing and disposing of Duspatalin (mebeverine hydrochloride) to maintain its stability.

Official Storage Conditions

Duspatalin must be stored at a temperature not exceeding 30^circC. It is prohibited to refrigerate or freeze the medicine. To ensure protection from moisture and light, the product must be kept in its original package.

For child safety, the medicine must be strictly kept out of the reach and sight of children.

Disposal Instructions

Any unused or expired product must be handled strictly in accordance with local requirements for pharmaceutical waste. The medicine should not be disposed of via household waste or wastewater to prevent environmental contamination.